Hamilton Lane (HLNE)
(Real Time Quote from BATS)
$141.58 USD
+1.69 (1.21%)
Updated Jul 22, 2024 11:56 AM ET
1-Strong Buy of 5 1
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HLNE 141.58 +1.69(1.21%)
Will HLNE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HLNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HLNE
Decent Equity Market to Aid T. Rowe Price (TROW) in Q2 Earnings
Will Lower Market Volatility Hurt Franklin's (BEN) Q3 Earnings?
HLNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for Principal Financial (PFG) in Q2 Earnings?
Are You Looking for a Top Momentum Pick? Why Hamilton Lane (HLNE) is a Great Choice
The Zacks Analyst Blog Highlights Hancock Whitney, UnitedHealth, Eni S.p.A, FedEx and Hamilton Lane
Other News for HLNE
Avista Capital, Hamilton Lane announce partnership in Cosette Pharmaceuticals
Avista Capital Partners and Hamilton Lane Announce Partnership in Cosette Pharmaceuticals
Avista Capital, Hamilton Lane announce partnership in Cosette Pharmaceuticals
Hamilton Lane Incorporated to Announce First Quarter Fiscal 2025 Results on August 6, 2024
Canoe Intelligence Raises $36 Million Series C Funding Led by Goldman Sachs to Further Market Expansion